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Abstract
Protein chemistry, such as crosslinking and photoaffinity labeling, in combination with modern
mass spectrometric techniques, can provide information regarding protein-protein interactions
beyond that normally obtained from protein identification and characterization studies. While
protein crosslinking can make tertiary and quaternary protein structure information available,
photoaffinity labeling can be used to obtain structural data about ligand-protein interaction sites,
such as oligonucleotide-protein, drug-protein and protein-protein interaction. In this article, we
describe mass spectrometry-based photoaffinity labeling methodologies currently used and discuss
their current limitations. We also discuss their potential as a common approach to structural
proteomics for providing 3D information regarding the binding region, which ultimately will be
used for molecular modeling and structure-based drug design.
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In photoaffinity labeling (PAL), a ligand possessing a UV-photoactivating group is
incubated with its receptor to form, first, a noncovalently bound ligand-receptor complex in
which the ligand binds specifically to the binding site or pocket in the receptor due to its
affinity. Some ligands, such as oligonucleotides, contain intrinsic photoactivating groups;
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alternatively, these groups can be introduced by synthesis into ligands for peptides and small
molecules, such as drugs. It is important to establish that the incorporated photoactivating
groups do not significantly alter the binding affinity of the ligand to its receptor and its
functionality, compared with the nonderivatized ligand. Subsequent to the complex
formation, UV irradiation triggers the photoactivating group in the ligand and leads to the
conversion of the noncovalent binding into a covalent link between the ligand and its
receptor at the binding site. A covalent ligand-receptor complex makes the study of the
complex easier, since it permits the use of more rigorous but harsher analysis tools, such as
SDS-PAGE, HPLC and mass spectrometry (MS), which would typically lead to the
dissociation of the complex with information regarding the binding sites no longer being
obtainable.
Photoaffinity labeling with radioactively labeled ligands is a widely used method to
determine the competitive binding affinities of other molecules for the binding sites in the
binding pocket occupied by the radioactively labeled ligand and, as such, is a valuable tool
for drug screening. When photoaffinity techniques are combined with modern MS, this
approach can provide additional structural and mechanistic information regarding the
protein complex, such as the ligand-receptor stoichiometry, a map of the binding pocket, and
even the exact identification of the amino acid residues, which are involved in the ligand-
receptor interaction. The data obtained can be used to create a 3D model of the ligand-
binding pocket that might provide better insight into the nature of the ligand-receptor
interaction. This knowledge can be very valuable, not only for better determination of the
mechanism of interaction, but also for structure-based drug design in order to generate more
potent drugs.
General principles of photoaffinity labeling for structural analysis
Photoaffinity labeling is a valuable technique for studying the interaction of ligands with
their target proteins, such as receptor proteins. Although the technique was initially
developed and described more than four decades ago by Singh, Thornton, and Westheimer
[1], the basic principles of photoaffinity labeling remain essentially unchanged today. In this
technique, ligands possessing photoactivating probes are irradiated with UV-light after the
formation of the ligand-receptor complex. Photolysis results in the creation of highly
reactive intermediates, mainly carbenes and nitrenes, which will form covalent bonds with
receptor proteins and thereby covalently attach the ligand at their receptor-binding site.
Three types of photoactivating probes are mainly used in photoaffinity labeling: azido
groups, benzophenone groups and diazirenes. Furthermore, photoaffinity labeling containing
additional groups, for example biotin, stable isotopes and fluorescence groups, facilitates the
detection and identification of the photolabeled biomolecules. The ligand-receptor complex
can be isolated via HPLC and analyzed by MS. The accurate measurement of the molecular
weight of the complex provides information on the number of ligands covalently bound to
each molecule of receptor, thus providing information on the stoichiometry of the complex
and specificity of the photolabel. In order to identify the site of ligand-receptor interaction,
the complex is typically digested and the peptide(s) containing the covalently linked ligand
is analyzed by mass spectrometric or combined chromatographic and MS approaches.
Figure 1 details general steps involved in photoaffinity labeling experiments combined with
MS for structural analysis of protein-ligand complexes to determine receptor-ligand
stoichiometry and identify ligand binding sites.
Photolabels
The choice of photoactivating group used to covalently link ligand and receptor is the
critical design component of each photoaffinity labeling experiment. In most PAL
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experimental situations, the photolabeling reagent is typically a derivatized receptor
substrate. An appropriate photoactivating group is usually synthetically inserted into the
ligand of interest, although some ligands may contain moieties capable of intrinsic photo-
activation (e.g., sulfides, enones, dienones and halogenated compounds) [2]. A number of
variables will affect the outcome of a PAL experiment and, therefore, selection of an
appropriate photoactive group as a probe for any given ligand-receptor complex is not a
trivial concern. The choice of probe should be well thought out and extensively evaluated
with the ligand of interest to ensure that it satisfies certain critical criteria. Ideally, the
photoreactive group chosen as a probe for a PAL experiment should demonstrate as many of
the following characteristics as possible [3,4]. First, the photophore molecule should be as
small as possible so that when it is incorporated into the ligand it does not create any steric
interference that would act to deleteriously impact ligand-receptor binding affinity. Once a
probe is chosen, control experiments should be performed prior to PAL experiments to
ensure that the binding affinity of the derivatized ligand for its receptor is not significantly
altered in relation to that of the nonderivatized ligand. In addition to steric considerations,
the photophore should demonstrate reasonable chemical stability under both ambient light
conditions and in darkness.
Another critical consideration concerns the lifespan of the photo-activated state once
activated by UV irradiation. The life span should be of short enough duration so that
covalent linkage between the photophore and receptor occurs before disassociation of the
ligand-receptor complex. Conversely, the excited state should last long enough for the
photophore to remain in close contact with the binding site so that sufficient covalent
bonding will be able to occur. The photophore should also be expected to generate only a
single unambiguous covalent adduct in order to avoid uninterpretable results. Finally, an
ideal photophore should be capable of attacking both C–H and nucleophilic X–H bonds at
an activation wavelength that would not lead to photolytic damage to proteins. This last
criterion is quite important, because a stable covalent complex permits the use of rigorous
(but often harsh) analytical tools, such as electrophoresis and MS, in examining the structure
of protein receptor-ligand complexes. Without a stable covalent linkage, the use of
electrophoresis, chromatography and/or mass spectrometric techniques in downstream
analyses would likely promote dissociation of the ligand-receptor complex and lead to
ambiguous results.
The overwhelming majority of photophore reagents currently used in PAL studies of protein
structure and function are based on the reactivity of nitrenes or carbenes. Nitrenes and
carbenes demonstrate very similar chemistries and as they are strong electrophiles they are
capable of reacting rapidly with double bonds or heteroatoms (e.g., N, O or S) with pairs of
nonbonding electrons. However, the predominance of nitrene- or carbene-based reagents in
photoaffinity labeling studies of protein interactions is largely due to the ability of these
chemical groups to attack even 'inert' aliphatic C–H bonds [3]. The broad reactivity of
photoaffinity reagents based on these chemistries essentially means that almost all functional
groups that are found in biomolecules such as proteins are available for forming covalent
linkages.
The most commonly employed photoactivating probes currently utilized in photoaffinity
labeling studies are aryl azides, aryl diazirines and benzophenone compounds [5,4]. The aryl
azide and diazirine photoactivating compounds are generally precursors of nitrene and
carbene reactive groups, while the benzophenone based compounds rely on the
photochemical reactivity of aryl ketones for the formation of covalent linkage between a
ligand and receptor [6]. While all three probe types are well represented in the photoaffinity
labeling literature, benzophenone-based photoprobes have some distinct advantages that
have led to them being particularly appealing for use in studies of protein structure and
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interaction. Benzophenone groups generally possess greater chemical stability than their
azide and diazirine counterparts [6], and they may be manipulated in ambient light without
significant degradation and then activated at a wavelength sufficiently high enough to avoid
protein denaturation that may result from the use of photophores that require activation at
low UV wavelengths [6]. In addition, the benzophenones retain their stability in many
common protic solvents [4] and another benefit of particular relevance to the study of
biological molecules is that benzophenone photophores remain reactive with C–H bonds,
even in the presence of water [3,6]. Weber and Beck-Sickinger conducted a useful study
comparing the crosslinking efficiency, influence of water on crosslinking, irraditation
requirements and by-product formation for azide, diazirine and benzophenone photoprobes
[5]. The authors discuss some advantages and disadvantages that would be of concern to
researchers in the planning stages of a PAL-based study.
To facilitate further study of the ligand-receptor complex, photoaffinity probes often contain
a 'tag' in addition to the photoactivating moiety. This tag usually takes the form of a
radioactive, fluorescent and stable isotope, or immunoreactive constituent, and is especially
useful when attempting to identify the receptor for a ligand of interest in a complex matrix,
such as a cell lysate. The tag enables the covalently linked ligand-receptor complex to be
detected during subsequent isolation and characterization steps.
When combined with the power of MS, photoaffinity labeling techniques enable information
on receptor-ligand interactions to be obtained on several levels. For instance, these
techniques can be used to screen for binding proteins specific for a particular ligand or drug
candidate. Once a binding protein is identified and isolated, the binding region itself can be
localized by fragmentation of the protein into peptide fragments followed by MS-based
sequencing. Finally, PAL facilitates identification of the amino acids involved in interaction
with the ligand in the binding pocket. The data obtained at this level are useful in developing
models of the 3D structure of the ligand-receptor complex, and this valuable information is a
key component of effective structure based drug design [4].
In this article, we will highlight some of the exciting ways in which photoaffinity labeling is
being combined with proteomics techniques to answer questions at the forefront of structural
proteomics and drug development. We will discuss the predominant techniques in light of
both their promise and current limitations, as well as presenting a perspective on the future
developments in photoaffinity labeling/MS-based proteomics in the coming years.
Protein-DNA interaction
Although the use of MS in conjunction with photolabeling is most often used to study
protein-protein and protein-small molecule interactions, several reports illustrate the
emerging utility of strategies involving photolabeling combined with MS for studying the
molecular interactions between proteins and nucleic acids. Interactions between proteins and
DNA play fundamental roles in cellular biology and disease processes. A variety of protein
classes interact with DNA, including polymerases, histones, ribosomes and various
transcription factors. Developing drugs to treat disease states involving these proteins
necessitates a thorough understanding of how they interact with nucleic acids in the cell.
NMR spectroscopy and X-ray diffraction are two of the most common traditional analytical
methodologies for studying protein-DNA interactions [7,8], but recently MS has emerged as
a promising new technique in this field [9]. Inducing covalent linkage between proteins and
DNA through photo-activation of intrinsic photosensitive functional groups following
complex formation has the advantage of stabilizing the often weak noncovalent interactions
involved without greatly perturbing the binding interface. Covalent linkage paves the way
for downstream purification and analysis of the interaction site sequence using
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electrophoresis, chromatography and MS. Another advantage of this approach is that it can
provide information regarding the identity and location of binding sites with more detail,
greater sensitivity, and less analysis time than the more traditional biophysical techniques.
Benzophenone [10], azido-, thio-, iodo- and bromo-based [11] photoactivating nucleotide
analogs have been used to create covalent linkages between proteins and DNA, in addition
to UV-induced crosslinking through intrinsic photoactive groups in native proteins and
DNA. The advantage of using substituted photoactivating analogs is that activation can be
achieved at wavelengths above 300 nm, thereby avoiding many problems associated with
UV-induced protein degradation [9]. Golden and colleagues demonstrated the utility of
using a substituted DNA in conjunction with MS to characterize protein-DNA interfaces
[12]. By substituting photoactive 5-bromo-2′ -deoxyuridine for thymidine and activating
with a XeCl excimer laser at 308 nm they crosslinked a high-affinity single-stranded DNA
aptamer to basic fibroblast growth factor (bFGF)155, an important protein regulator of cell
proliferation and differentiation. The bFGF155 complex was then tryptically digested,
purified and isolated by electrophoresis, digested again with phosphodiesterase/alkaline
phosphatase, and then analyzed by HPLC/electrospray ionization (ESI)-MS. Comparison of
mass spectra for the digested, uncrosslinked oligonucleotide and the digested complex
revealed a single fragment unique to the complex. MS/MS sequencing of this fragment
confirmed this as the site of covalent linkage, and provided the primary sequence of the
binding pocket. However, a common drawback to this type of approach is the typical need
for large amounts of starting protein due to the potential of low protein-DNA complex yields
obtained with some photophores, and low complex recovery as a result of losses during the
subsequent electrophoresis or liquid chromatography steps [11] necessary to remove
peptides and free DNA that may lead to MS ionization suppression [13]. These drawbacks
have limited the full exploitation of highly sensitive MS techniques as a complement to
photolabeling for the study of protein-DNA interactions.
Geyer and colleagues recently described a novel approach to improve the sensitivity of MS
analyses of protein-DNA complexes by eliminating the need for loss-inducing
electrophoresis or reversed-phase HPLC separations prior to MS[14]. They incorporated
photoreactive 5-iododeoxyuridine (5-IdU) into a single site within the sequence of DNA
known to interact with the bacterial restriction endonuclease MboI. Following UV-induced
covalent linkage and proteolytic digestion, oligodeoxynucleotide-linked fragments of MboI
were enriched by Fe3+-immobilized metal affinity chromatography (IMAC) [13]. The size
of the oligodeoxynucleotide was then reduced to a single dU residue attached to the peptide
by hydrogen fluoride hydrolysis. MALDI-TOF-MS and MALDI-TOF MS/MS were then
used to identify and characterize the DNA-binding region of MboI. This strategy not only
reduces losses during covalent-complex purification, it greatly reduces the amount of
unwanted analytes in the sample and thereby obviates the need for other purification steps,
allowing protein-DNA interaction sites to be rapidly and efficiently characterized with less
than 500 pmol of protein starting material. Such innovations, when coupled to continuing
advances in MS capabilities, should only serve to solidify photolabeling coupled with MS as
the method of choice for defining and characterizing sites of protein-DNA interaction.
Protein interactions with small proteins & peptides
Physical interactions between protein molecules are central to all biological processes.
Understanding how these often complex networks of interacting proteins function in
governing biochemical phenomena in both normal and diseased cells on a global level is one
of the major aims of the emerging field of systems biology [15] and in drug discovery [16].
Consequently, research aimed at defining protein-protein interactions is of considerable
importance, and photoaffinity labeling has been a valuable tool for elucidating the identity
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of interacting protein partners for some time [17]. With the advent of the field of proteomics,
however, the information that can be obtained regarding protein-protein interactions by
combining photoaffinity labeling techniques with MS has grown tremendously [16,18]. By
integrating MS with PAL, researchers have not only identified binding partners for a
particular ligand or receptor of interest, but also localized and characterized the sites of
interaction at a molecular level [19–25] with far greater efficiency and rapidity than could be
achieved with more traditional biophysical techniques. At the protein level, comparing the
mass of photolabeled protein-protein ligand-receptor complexes with that of unlabeled
material can be used to generate information on the stoichiometry of interactions [18]. By
proteolytically cleaving and then purifying a protein-protein oligopeptide photoadduct by
electrophoresis or chromatography, investigators can then use MS/MS-based peptide
sequencing techniques to determine the amino acid sequence of the binding regions of both
ligand and receptor protein. This capacity to define the primary structure of interaction sites
makes combining PAL with MS a very powerful strategy for structure-based drug design
[4,16].
Recent advances aimed at employing new and novel MS techniques are expanding the
potential of photoaffinity labeling as a protein-protein interaction discovery tool. Sachon and
colleagues [26] incorporated the use of biotin/streptavidin purification of photolabeled
complexes [20] with isotope-coded affinity tag (ICAT) methods [27] to dramatically
enhance the sensitivity of MS-based photoaffinity labeling techniques. By incorporating a
deuterium-labeled p-benzoyl-phenylalanine photoreactive group into substance P and using
this probe to label the human NK-1 receptor, the investigators used MALDI-MS to
discriminate the photolabeled complex based on double peaks separated by the mass
difference between the deuterated and nondeuterated species following digestion of the
complex and biotin/streptavidin purification. Using this approach, very minute amounts of
protein-protein complex in the subpicomolar range can be confidently characterized.
Jahn and colleagues recently reported the use of optimized liquid chromatography (LC)
separation of photolabeled protein-protein complexes in conjunction with multiple ion
chromatogram (MIC) on-line ESI-MS to characterize low abundance complexes [18].
Special reversed-phase LC columns compatible with formic acid enabled them to eliminate
the ion suppression effects commonly observed with the reversed-phase ion paring agent
trifluoroacetic acid (TFA), resulting in a one order of magnitude increase in MS sensitivity.
In addition, they demonstrated that the use of MIC in conjunction with optimized LC/MS
can dramatically further increase sensitivity in experiments aimed at localizing protein-
protein interaction sites in low abundance complexes [28]. They extracted multiple ion
chromatograms from LC total ion chromatograms in an extension of the selected ion
extraction technique. This allowed for detection of corticotropin-releasing factor binding
protein (CRFBP) and CRFBP-urocortin analog complexes from LC/ESI-MS chromatograms
with an additional order of magnitude increase in sensitivity. As MS instrumentation and
methods continue to evolve in conjunction with advances in techniques such as nanoscale
LC, photoaffinity labeling techniques can be expected to become even more widely used
tools for characterizing protein-protein interactions and for generating structural information
for use in drug design.
Protein-small molecule interaction
Obtaining a thorough understanding of the molecular interactions between small bioactive
ligands and their corresponding receptor proteins is a critical step in the drug discovery
process. Protein interactions with a variety of chemical entities play a central role in the
etiology of many disease processes, and proteins are often directly involved in metabolizing
therapeutic compounds and mediating their transport into or out of cells. Consequently,
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understanding these phenomena on a molecular level is currently a high-priority area of
research. Photoaffinity labeling-MS integrated techniques are exceptionally well suited to
addressing many pertinent research questions regarding protein-small molecule interactions,
including identifying binding partners of specific ligands or protein receptors of interest,
elucidating or characterizing the binding or interaction site, determining the stoichiometry of
interactions, and in assisting the development of structural models for use in design of new
chemotherapeutic agents.
Identifying or characterizing the ligand-binding site within a protein receptor is perhaps the
most common application of photoaffinity labeling-MS techniques at present. PAL in
conjunction with MALDI-MS and/or LC/MS analysis of protein-small molecule covalent
complexes enables investigators to rapidly and accurately identify sites of interaction based
on detecting mass additions due to ligand attachment. Subsequent proteolytic digestion of
the isolated protein-ligand complex and MS-based sequencing can, in turn, reveal the
sequence of the amino acids in the ligand-binding region and provide valuable information
regarding the potential binding chemistry. These techniques have been used to define a wide
variety of binding sites on protein receptors including those for allosteric regulation of
enzyme substrate specificity [29], bile acid transport protein [30], alkyl glucoside inhibitors
of glucose cotransport protein [31], allosteric inhibitors of protein-protein interactions [32],
inhibitors of enzyme activity [33], visual cycle enzyme substrates [34], substrate-binding
sites of cytochrome P450 [35], and substrate-binding domains of the drug-efflux mediator P-
glycoprotein [36–38]. In addition to identifying and characterizing binding sites in known
protein receptors, several groups have demonstrated the promise of combining proteomics
with PAL to identify protein targets for candidate drugs [39,40].
Davidson and colleagues recently demonstrated the ability of PAL combined with micro-LC
and Fourier-transform ion cyclotron resonance MS (FT-ICR/MS) to pinpoint the location of
photolabel incorporation with atomic resolution [41]. The unparalleled resolving power and
mass accuracy achievable with FT-ICR/MS [42], when combined with micro-LC
techniques, can lead to highly accurate detection of peptides present as low as the attomolar
range [43]. Davidson and colleagues combined these techniques with benzophenone-based
photolabeling to localize the binding site for inhibitors on the human papillomavirus (HPV)
E2 protein that inhibits its interaction with HPV E1 helicase. Following proteolytic digestion
of the complex, micro-reversed phase LC and on-line FT-ICR/MS characterization of the
resulting peptides pinpointed the site of photolabel incorporation to the terminal carbon
atom of a single Met residue within the ligand-binding pocket.
Another important application of MS in combination with photoaffinity labeling techniques
is in the determination of the stoichiometry of protein-small molecule interactions. The
accurate mass measurement of the molecular weight of the photoaffinity protein-ligand
complex compared with the unlabeled protein provides information on the number of
molecules of ligand covalently bound to each molecule of protein. ESI is a gentle ionization
technique that is particularly amenable to accurate mass measurement of even large proteins,
and Lafitte and colleagues demonstrated the potential of ESI-MS in determining the
stoichiometry of various calmodulin-pyrazine derivative complexes [44]. More recently,
Wen and colleagues used ESI-MS to investigate both the site of substrate binding in
cytochrome P450 and the stoichiometry of the interaction [35]. In our own laboratory, we
have employed ESI-MS in combination with photoaffinity labeling to characterize the
binding site and stoichiometry for interaction between HIV integrase and an inhibitor of this
protein, coumarin [45]. Figure 2 shows the shift in molecular weight of HIV-integrase due to
the incorporation of coumarin by photoaffinity labeling, and demonstrates how the accurate
mass measurement obtainable with ESI-MS can easily discriminate the addition of just a
single small molecule ligand to a protein receptor. A tryptic digest of the photolabeled
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integrase-coumarin complex produced peptides that were separated by HPLC. Peptide
fractions demonstrating a difference in UV absorbance at 280 nm as compared with control
digests were analyzed by LC/ESI-MS. Using this approach, we identified a single binding
site for the inhibitor in the tryptic peptide 128AACWWAGIK136. Site-directed mutagenesis
of the full-length integrase followed by in vitro inhibition assays implicate two specific
residues, C130 and W132, as being involved in inhibitor binding. The approach we used
here is particularly useful for characterizing the stoichiometry of protein-ligand complexes
that are difficult to analyze by X-ray crystallography and NMR techniques.
With regard to drug development and design, once information regarding the location and
stoichiometry of protein-ligand interactions is obtained, the next step is to develop 3D
models of the complex [32,38,46]. Structural models of protein-binding sites can then be
used to conduct molecular modeling experiments to identify novel compounds that may
have high affinity for the binding site, or screen the affinity of existing compounds
computationally.
Based on PAL-MS experiments in our laboratory with HIV-integrase and the coumarin
inhibitor, we identified and characterized a single novel site for coumarin attachment in the
integrase and used the PAL data to conduct molecular modeling experiments in order to
better define the inhibitor-enzyme complex and propose a mechanism of action. Molecular
docking studies using the genetic optimization for ligand docking (GOLD) algorithm
indicated the integrase inhibitor binds close to the dimeric interface of the integrase core
domain (see Figure 3). Site-directed mutagenesis of selected amino acid residues in the
PAL-MS-identified binding region conferred resistance to coumarin and confirmed this as
the drug-binding site (Figure 3). In addition, modeling enabled us to identify more than 300
molecules that are predicted to have high binding affinities for the same drug-binding site
[unpublished results]. These results demonstrate the wealth of information that can be
obtained from photoaffinity labeling-MS experiments when that data is combined with site-
directed mutagenesis studies and molecular modeling techniques. The structural information
derived from these types of studies can shed light on potential mechanisms of drug action
and thereby assist in the design of additional therapeutic agents.
Expert commentary
3D structural data about binding sites and pockets in protein-ligand and protein-biomolecule
complexes are of major interest for the biomedical research community since valuable
information regarding mechanistic knowledge of protein-protein and protein-ligand
interactions can be derived, which are crucial for structure-based drug design. Currently, the
methods of choice for structural analysis of these interactions are X-ray crystallography and
NMR as both techniques can achieve atomic resolution. Although tremendous
improvements have been made in recent years in both techniques, they are still somewhat
limited, especially for the analysis of large complexes under native conditions, as would be
found with high-molecular-weight receptor proteins embedded in membrane vesicles. In
general, the combined approach of photoaffinity labeling and MS is adequate to provide
information regarding binding sites and pockets. We believe that this approach is
particularly useful in cases where structural analysis of the complexes via X-ray and NMR is
not possible. Especially constructive is the use of PAL-MS techniques in combination with
molecular modeling to obtain 3D information regarding the interaction, as we have
demonstrated for the drug binding sites of HIV-integrase.
Five-year view
The combined approach of photoaffinity labeling and MS has great potential as a
complementary technique to X-ray crystallography and NMR. In general, the
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instrumentation and skills necessary for conducting PAL combined with MS experiments
designed to identify ligand- or peptide-binding sites are accessible to most laboratories. The
primary impediment to more widespread utilization of PAL-MS techniques is the need for
expertise in several fields, (e.g., MS, biology, biochemistry, synthetic chemistry and
molecular modeling). However, we feel that use of PAL combined with MS to address
questions in structural biology will increase in the coming years as improvements in MS
make it more practical for a larger number of laboratories.
One of the major technical challenges associated with PAL combined with MS is the
detection and identification of the photolabeled products. In general, with increasing sample
complexity detection becomes more difficult, due to mass spectrometric ionization
suppression effects and instrumental limitations related to resolution, mass accuracy and
dynamic range. However, recent instrumental and methodological improvements have
demonnstrated that the limitations can be circumvented. For example, high-field FT-ICR
and orbitrap mass spectrometers, instruments that are distinguished by ultra-high resolution
and mass accuracy, and the highest dynamic range, respectively, offer promise in
overcoming some of these limitations. In addition, novel mass spectrometric-based methods
(such as top-down proteomics, where intact protein or protein complexes are directly
analyzed using newly developed dissociation mechanisms such as electron capture
dissociation [ECD] and electron transfer dissociation [ETD]) are showing great promise as
useful tools for the combined approach of PAL and MS. ECD and ETD are mechanisms that
lead mainly to fragmentation of the peptide backbone while keeping post-translation
modifications intact, such that even very labile modifications such as carboxylated glutaric
acid residues remain undamaged during MS-based peptide sequencing. Thus, these methods
seem to be ideal to precisely identify the binding site of photolabels by sequencing
photolabeled proteins and peptides.
In 5 years, we expect that with exploitation of these novel mass spectrometric techniques
and methods, coupled with more sophisticated 'MS friendly' (isotopically labeled) photo-
probes and better knowledge of the photochemical reaction, the combined approach of PAL
and MS will be a significant alternative to NMR and X-ray crystallography. In particular, we
believe that PAL combined with MS will have a great impact in the area of identifying drug-
binding sites in membrane-located protein receptors (the main target proteins for drugs) and,
therefore, this approach will be of great interest and use for the pharmaceutical industry.
Key issues
• Understanding protein-nucleic acid, protein-protein and protein-small molecule
interactions on a molecular level is essential to drug discovery and development.
• Photoaffinity labeling is a very powerful biochemical tool for studying molecular
interactions, especially when NMR and X-ray chrystallography is impractical.
• When combined with mass spectrometry (MS) techniques, photoaffinity labeling is
a useful tool for identifying protein ligands, discovering what protein(s) in the cell
a particular ligand or drug targets, determining the stoichiometry of protein-ligand
interactions and elucidating the primary structure of protein ligand-binding regions.
• The data derived from photoaffinity-MS studies can be used to develop models for
characterizing drug-target interactions as part of structure-based drug design efforts
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General schema of photolabeling-mass spectrometry experiments. (A) Following interaction
of the protein of interest with a photolabeled ligand, the complex is covalently linked by UV
irradiation. Isolation of the covalent complex followed by MS allows for identification of
binding protein, determination of the ligand:protein stoichiometry, and identification and
sequencing of the ligand-binding region of the protein. We used this approach to localize the
binding site for an inhibitor of the HIV-1 integrase protein. (B) Alternatively, if the receptor
protein is known, the purified protein may be subjected to direct LC-MS following ligand
binding, crosslinking and tryptic digestion. This approach may be advantageous when
dealing with hydrophobic ligands that may be lost during HPLC separation. HPLC: High-
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performance liquid chomatography; LC: Liquid chromatography; MALDI: Matrix-assisted
laser desorption/ionization; MS: Mass spectrometry; UV: Ultraviolet.
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Deconvoluted ESI-MS spectra of (left panel) HIV-integrase and (right panel) HIV-integrase
after photoaffinity labeling with the HIV-integrase inhibitor coumarin (R61). (A): the base
peak at m/z 19,954 agrees precisely with the MW of HIV-integrase as calculated from the
amino acid sequence. The additional peaks at higher m/z can be assigned to oxidation
products and β-mercaptoethanol adducts. (B): due to the presence of the photoaffinity label,
the peaks are shifted to higher m/z values by 516 Da, which agrees precisely with the
expected mass increment for addition of one coumarin molecule. ESI: Electrospray
ionization; MS: Mass spectrometry; MW: Molecular weight.
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Model of a single HIV integrase dimer rendered by helix. Yellow represents the inhibitor
binding region peptide 128AACWWAGIK136. Blue represents one molecule of the coumarin
inhibitor complexed within the binding site determined by PAL-MS. Cyan represents the
integrase active site residues (DDE motif) and the sphere is Mg2+ chelating at this site. MS:
Mass spectrometry; PAL: Photoaffinity labeling.
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